
Opinion|Videos|August 8, 2024
Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis
Author(s)Paul Frohna, MD, PhD
Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.
Advertisement
- What were the key updates for treatment in the 2022 ATS Guidelines and what additional information is needed in future iterations?
- How do you see the guidelines changing as novel agents enter the treatment landscape?
- There were no FDA-approved therapies for IPF/PPF prior to anti-fibrotic agents. How have these therapy options altered treatment of the disease?
Advertisement
Related to this article

Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.

The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.

Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.

Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.

In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.

Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.

Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
New pulmonary fibrosis drugs put guidelines in focus, Prusi says | AMCP Nexus 2026
2
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
3
Fewer than half of newly diagnosed children with type 1 diabetes get autoantibody testing
4
The ripple effects of Medicare’s maximum fair price with Hiva Pourarsalan, Pharm.D. | AMCP Nexus 2026
5



